PORTUGAL

Ukraine war: Pope Francis should learn from his WWII predecessor’s mistakes in appeasing fascism

Retrieved on: 
Wednesday, March 13, 2024

Pope Francis has provoked fury by suggesting in a television interview that Ukraine should find “the courage to raise the white flag”.

Key Points: 
  • Pope Francis has provoked fury by suggesting in a television interview that Ukraine should find “the courage to raise the white flag”.
  • As Pope Pius XII, Eugenio Pacelli led the Catholic Church throughout the second world war.
  • However, while Hitler’s determination to eliminate the Jewish people was brought to his attention, he did not publicly condemn it.
  • Though he admired the authoritarian regimes of Franco in Spain and Salazar in Portugal, Pius XII was not pro Nazi.

‘Catholics will be loyal’

  • He told the German chancellor:
    I am certain that if peace between Church and state is restored, everyone will be pleased.
  • The German people are united in their love for the Fatherland.
  • I am certain that if peace between Church and state is restored, everyone will be pleased.
  • He feared that criticism of Hitler’s regime would provoke harm to German Catholics.
  • In August 1942 Pius XII received a letter from Andrej Septyckj, a Ukrainian Cleric, bearing news of the massacre of 200,000 Jews in Ukraine.
  • Pius XII flirted with public criticism of Nazi inhumanity in his 1942 Christmas Eve broadcast.

Evil then and now

  • As I discovered while researching my book, Reporting the Second World War - The Press and the People 1939-1945, he could have learned as much by reading British newspapers.
  • In autumn 1942, titles including The Times and Daily Mail reported the World Jewish Congress’s belief that a million Jews had already died.
  • Today, his successor might contemplate the damage inflicted on his wartime predecessor’s reputation by his meek collusion with the wrong side.
  • Ukrainian foreign minister Dmytro Kuleba responded caustically to Pope Francis’s crass comments with: “Our flag is a yellow and blue one.


Tim Luckhurst has received funding from News UK and Ireland Ltd. He is a member of the Free Speech Union and the Society of Editors

EQS-News: Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer's disease transgenic model to be presented at AD/PD™ 2024 Conference

Retrieved on: 
Wednesday, March 13, 2024

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Kensington, MD, USA, February 28, 2024 –Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases, announced the presentation of new in vitro and in vivo data with orally available small molecule GAL-201, an amyloid beta aggregation modulator, in a transgenic model of Alzheimer's disease (AD) at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™ 2024).
  • The conference will take place March 5 - 9, 2024 in Lisbon, Portugal.
  • The following poster will be presented:
    Title: The amyloid beta aggregation modulator GAL-201 is under development for oral AD treatment: Cognitive improvement in a transgenic AD model
    The poster will include data showing the beneficial effects of GAL-201 in an established transgenic mouse model of AD, both in vitro as well as in behavioral experiments, showing its promise as a treatment of AD.

EQS-News: Symrise AG again raises sales significantly in 2023

Retrieved on: 
Wednesday, March 13, 2024

The Symrise Group generated sales of € 4,730 million in the 2023 fiscal year, an increase of 2.4 % in the reporting currency.

Key Points: 
  • The Symrise Group generated sales of € 4,730 million in the 2023 fiscal year, an increase of 2.4 % in the reporting currency.
  • Heinz-Jürgen Bertram, Chief Executive Officer of Symrise AG: “2023 was again a successful year of growth for Symrise.
  • Despite the good sales development in the 2023 fiscal year, earnings remained below expectations.
  • The cost of goods sold increased slightly faster than sales, which was mainly attributable to higher raw material and manufacturing costs.

EQS-News: 029 Group SE: Portfolio company Limestone Capital acquires luxurious hotel resort in Sardinia

Retrieved on: 
Wednesday, March 13, 2024

029 Group SE (ISIN: DE000A2LQ2D0), a global hospitality and lifestyle platform, announces that its portfolio company Limestone Capital AG, a leading alternative asset manager with a focus on hospitality and travel, has bolstered its Italian presence with the acquisition of a luxurious resort hotel in Costa Smeralda, Sardinia.

Key Points: 
  • 029 Group SE (ISIN: DE000A2LQ2D0), a global hospitality and lifestyle platform, announces that its portfolio company Limestone Capital AG, a leading alternative asset manager with a focus on hospitality and travel, has bolstered its Italian presence with the acquisition of a luxurious resort hotel in Costa Smeralda, Sardinia.
  • The acquisition marks a significant addition to the growing portfolio of four hotels in Italy.
  • Benjamin Habbel, CEO of Limestone Capital, expresses his enthusiasm for this acquisition, stating, "This acquisition represents a great milestone for Limestone Capital by expanding our presence in Italy and adding a luxurious asset in a globally renowned resort destination to our European portfolio.
  • The acquisition of the Sardinia hotel marks a significant milestone in bringing this vision to fruition.

Akurateco Acquires Google Pay Certification as a Payment Gateway

Retrieved on: 
Friday, February 23, 2024

Lisbon, Portugal--(Newsfile Corp. - February 23, 2024) - Akurateco, a European-based global white-label payment software provider, proudly announces its recent certification as a participating processor for Google Pay.

Key Points: 
  • Lisbon, Portugal--(Newsfile Corp. - February 23, 2024) - Akurateco, a European-based global white-label payment software provider, proudly announces its recent certification as a participating processor for Google Pay.
  • As a certified white-label payment gateway, Akurateco is prominently featured on Google Pay's list of participating processors .
  • The certification positions Akurateco among the selected gateways and payment processors authorized to support the Google Pay Application Programming Interface (API).
  • Businesses partnering with Akurateco can now seamlessly integrate Google Pay into their payment processes, providing customers with a convenient and trusted payment experience.

Spacely AI Raises Pre-Seed Funding From SCB 10X and Launches Spatial Design APIs

Retrieved on: 
Thursday, March 7, 2024

The funding will fuel Spacely AI's mission to empower everyone with the opportunity to design their own success and position Spacely AI as the go-to platform in spatial design.

Key Points: 
  • The funding will fuel Spacely AI's mission to empower everyone with the opportunity to design their own success and position Spacely AI as the go-to platform in spatial design.
  • "SCB 10X is proud to back Spacely AI and their mission to unlock productivity and creativity for designers.
  • "The backing from SCB 10X is a partnership that aligns with our vision to transform the spatial design landscape.
  • Join Spacely AI in this exciting journey to redefine spatial design with Generative AI.

BioVie Announces Pipeline Update and Near-Term Clinical Priorities

Retrieved on: 
Monday, March 11, 2024

CARSON CITY, Nev., March 11, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that its recently completed funding round provides opportunity to further the Company’s clinical priorities in Parkinson’s Disease (PD), Alzheimer’s Disease (AD), and ascites/liver disease. The Company continues to explore longevity and aging in conjunction with external collaborators. 

Key Points: 
  • The Company continues to explore longevity and aging in conjunction with external collaborators.
  • The trial targets enrolling 100-150 patients in a 6-month trial with the Part 3 (motor) score on the MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) as the primary endpoint.
  • Only one Phase 3 trial is potentially needed as BIV201 has already received Orphan and Fast Track designations.
  • BIV201 remains our most de-risked program, but it unfortunately is a program that will take two years to complete.

Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference

Retrieved on: 
Monday, March 11, 2024

BRISBANE, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases and their substrates, a new class of enzymes discovered in-house that are implicated in a broad variety of diseases, today announced an abstract titled “Unveiling of a Novel Therapeutic Antibody Targeting Nitrated Alpha Synuclein for the Treatment of Parkinson’s Disease” was featured in an oral presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference taking place in Lisbon, Portugal from March 5-9, 2024. The presentation outlined data with Nitrase’s first-in-class antibody targeting extracellular nitrated alpha-synuclein (α-synuclein) for the treatment of Parkinson’s disease (PD) and other synucleinopathies. Nitrase’s antibody demonstrated both high affinity and selectivity for nitrated synuclein, and it demonstrated the ability to significantly reduce PD progression in in vitro and in vivo PD models.

Key Points: 
  • The presentation outlined data with Nitrase’s first-in-class antibody targeting extracellular nitrated alpha-synuclein (α-synuclein) for the treatment of Parkinson’s disease (PD) and other synucleinopathies.
  • A hallmark of PD pathology is the presence of Lewy Bodies and Lewy Neurites, which have been found to include an accumulation of nitrated α-synuclein.
  • It has been established in published studies that PD pathology spreads between brain regions along neural circuitry through extracellular aggregated α-synuclein.
  • Additionally, our antibody demonstrated superiority in a preclinical efficacy evaluation against the parental antibody of  prasinezumab, which targets non-nitrated α-synuclein.

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference

Retrieved on: 
Friday, March 8, 2024

BOTHELL, Wash., March 08, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented new clinical and preclinical data further highlighting the therapeutic potential of fosgonimeton at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, being held in Lisbon, Portugal March 5 – 9, 2024.

Key Points: 
  • Fosgonimeton is a potentially first-in-class investigational small molecule designed to positively modulate the hepatocyte growth factor (HGF) system, which can activate neuroprotective, neurotrophic and anti-inflammatory pathways in the central nervous system.
  • “We believe safety and efficacy outcomes from the exploratory SHAPE Phase 2 clinical trial presented at this year’s AD/PD, along with previous clinical data, support the continued development of fosgonimeton.
  • These findings support the potential therapeutic benefit of modulating the neurotrophic HGF system with fosgonimeton for neurodegenerative diseases.
  • “We’re pleased to be presenting additional preclinical data highlighting the neuroprotective effects of fosgonimeton in models of both Alzheimer’s and Parkinson’s diseases at AD/PD 2024,” said Kevin Church, Ph.D., Chief Scientific Officer of Athira.

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

Retrieved on: 
Friday, March 8, 2024

CHARLOTTESVILLE, Va., March 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today presented cerebrospinal fluid (CSF) biomarker data from the sabirnetug (ACU193) Phase 1 INTERCEPT-AD trial in an oral presentation at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD) in Lisbon, Portugal, and online. Acumen also presented a poster showcasing the method used to develop a first-of-its-kind assay to measure target engagement of an AβO-selective antibody.

Key Points: 
  • Acumen also presented a poster showcasing the method used to develop a first-of-its-kind assay to measure target engagement of an AβO-selective antibody.
  • Acumen’s sabirnetug is the first humanized monoclonal antibody to clinically demonstrate selective target engagement of AβOs, a soluble and highly toxic form of Aβ that accumulates early in AD and triggers synaptic dysfunction and neurodegeneration.
  • Positive topline results from 62 participants dosed in the Phase 1 INTERCEPT-AD trial (NCT04931459) were reported in July 2023 , and additional insights from exploratory analyses have further confirmed sabirnetug’s proof-of-mechanism and broad therapeutic potential as a next-generation treatment for early AD.
  • The novel assay configuration was tailored to selectively detect sabirnetug-AβO complex in CSF as a direct measure of target engagement, showing clear dose-related increases in target engagement across all cohorts.